biostudies-literatureSchwarze JKStichting Tegen KankerOncology Center Vrije Universiteit BrusselKom op tegen Kanker (Stand up to Cancer), the Flemish cancer societye005141https://www.ebi.ac.uk/biostudies/studies/S-EPMC9486335biostudies-literatureUnknown10(9)<h4>Background</h4>Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals and enhancing the release of tumor antigens that can be captured and processed by CD1c (BDCA-1)⁺ / CD141 (BDCA-3)⁺ myDCs, in order to reinvigorate the cancer-immunity cycle.<h4>Methods</h4>In this phase I trial, patients with advanced melanoma who failed standard therapy were eligible for IT injections of ≥1 non-visceral metastases with T-VEC on day 1 followed by IT injection of CD1c (BDCA-1)⁺ myDCs +/- CD141 (BDCA-3)⁺ myDCs on dayJournal for immunotherapy of cancerIntratumoral administration of CD1c (BDCA-1)⁺ and CD141 (BDCA-3)⁺ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.PMC9486335N/A111022016-128Awada GCras LNeyns BSchwarze JKTuyaerts SBagnall CTijtgat JVan Riet IVasaturo AForsyth RDufait IfalseIntratumoral administration of CD1c (BDCA-1)⁺ and CD141 (BDCA-3)⁺ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.<h4>Background</h4>Intratumoral (IT) myeloid dendritic cells (myDCs) play a pivotal role in initiating antitumor immune responses and relicensing of anti-tumor cytotoxic T lymphocytes within the tumor microenvironment. Talimogene laherparepvec (T-VEC) induces immunogenic cell death, thereby providing maturation signals and enhancing the release of tumor antigens that can be captured and processed by CD1c (BDCA-1)⁺ / CD141 (BDCA-3)⁺ myDCs, in order to reinvigorate the cancer-immunity cycle.<h4>Methods</h4>In this phase I trial, patients with advanced melanoma who failed standard therapy were eligible for IT injections of ≥1 non-visceral metastases with T-VEC on day 1 followed by IT injection of CD1c (BDCA-1)⁺ myDCs +/- CD141 (BDCA-3)⁺ myDCs on day2022-01-01T00:00:00Z2022 Sep2026-06-08T06:46:23.032Z2026-06-08T03:13:49.734ZS-EPMC94863353611389510.1136/jitc-2022-005141